Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex With Neutralizing Antibody 101F
Currently there is no effective vaccine against respiratory syncytial virus (RSV), but passive prophylaxis with neutralizing antibodies reduces hospitalizations. To investigate the mechanism of antibody-mediated RSV neutralization, the authors of this article, published in the Journal of Virology, undertook structure-function studies of monoclonal antibody 101F, which binds a linear epitope in the RSV fusion glycoprotein. The results of the studies provide a structural basis for RSV neutralization by antibodies that target a major antigenic site on the fusion glycoprotein. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: McLellan JS, Chen M, Chang JS, et al.
» Visit web page (English)
(Located at jvi.asm.org)
Citation: McLellan JS, Chen M, Chang JS, et al. Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex With Neutralizing Antibody 101F. Vaccine. 2010;84(23):12236-12244.
Resource types: Peer-reviewed journal
Diseases/vaccines: Respiratory syncytial virus (RSV)